Tranzyme Pharma To Report Fourth Quarter And Full-Year 2012 Financial Results

RESEARCH TRIANGLE PARK, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report fourth quarter and full-year 2012 financial results after the close of the market on Thursday, March 28, 2013.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of gastrointestinal (GI) disorders. All of the Company's product candidates have been discovered using its proprietary chemistry technology platform, MATCH™ (Macrocyclic Template Chemistry), which enables the construct of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. By leveraging MATCH™, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical need, and continues to seek collaborative drug discovery partnerships.
CONTACT: Corporate Inquiries:         Susan Sharpe         Director, Corporate Communications         (919) 328-1109         ssharpe@tranzyme.com

If you liked this article you might like

3 Health Care Stocks Under $10 to Watch

Tranzyme Stomach Paralysis Drug Comes Up Short

5 Stocks Under $10 Poised to Move Higher

Insiders Trading TZYM, ALKS, CAKE

For Biotech, 'Fail' is Making a Big Comeback